ID   TFK-1
AC   CVCL_2214
SY   TFK1
DR   CLO; CLO_0009330
DR   CLO; CLO_0050010
DR   BioSample; SAMN03471922
DR   BioSample; SAMN03473356
DR   cancercelllines; CVCL_2214
DR   Cell_Model_Passport; SIDM01462
DR   Cosmic; 927187
DR   Cosmic; 1122354
DR   Cosmic; 1373550
DR   Cosmic; 2674051
DR   DepMap; ACH-001673
DR   DSMZ; ACC-344
DR   DSMZCellDive; ACC-344
DR   RCB; RCB2537
DR   TKG; TKG 0367
DR   Wikidata; Q54972205
RX   CelloPub=CLPUB00275;
RX   PubMed=8693487;
RX   PubMed=9290701;
RX   PubMed=22490663;
RX   PubMed=27231123;
RX   PubMed=31077409;
RX   PubMed=32899426;
RX   PubMed=35640676;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Population: Japanese.
CC   Doubling time: ~37 hours (Note=At 40th passage) (PubMed=8693487); ~40 hours (DSMZ=ACC-344).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Trp91Ter (c.272G>A); ClinVar=VCV000233650; Zygosity=Homozygous (DepMap).
CC   Omics: Deep exome analysis.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Misspelling: TFKK-1; PubMed=22490663; Note=In supplementary figure 2.
CC   Derived from site: In situ; Extrahepatic bile duct; UBERON=UBERON_0003703.
ST   Source(s): DepMap; DSMZ; RCB; TKG
ST   Amelogenin: X,Y
ST   CSF1PO: 10
ST   D13S317: 14
ST   D16S539: 9
ST   D18S51: 16
ST   D19S433: 14,15
ST   D21S11: 30
ST   D2S1338: 18,22
ST   D3S1358: 17,18
ST   D5S818: 9,12
ST   D7S820: 10 (DSMZ)
ST   D7S820: 10,11 (DepMap; RCB; TKG)
ST   D8S1179: 13,14
ST   FGA: 20,23
ST   Penta D: 13,14
ST   Penta E: 5,18 (DepMap)
ST   Penta E: 18 (DSMZ)
ST   TH01: 6
ST   TPOX: 8
ST   vWA: 14,17
DI   NCIt; C4436; Cholangiocarcinoma
DI   ORDO; Orphanet_70567; Cholangiocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   63Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 27
//
RX   CelloPub=CLPUB00275;
RA   Zach S., Birgin E., Ruckert F.;
RT   "Primary cholangiocellular carcinoma cell lines.";
RL   J. Stem Cell Res. Transplant. 2:1013-1013(2015).
//
RX   PubMed=8693487; DOI=10.1620/tjem.177.61;
RA   Saijyo S., Kudo T., Suzuki M., Katayose Y., Shinoda M., Muto T.,
RA   Fukuhara K., Suzuki T., Matsuno S.;
RT   "Establishment of a new extrahepatic bile duct carcinoma cell line,
RT   TFK-1.";
RL   Tohoku J. Exp. Med. 177:61-71(1995).
//
RX   PubMed=9290701; DOI=10.1002/(SICI)1098-2744(199708)19:4<243::AID-MC5>3.0.CO;2-D;
RA   Jia L.-Q., Osada M., Ishioka C., Gamo M., Ikawa S., Suzuki T.,
RA   Shimodaira H., Niitani T., Kudo T., Akiyama M., Kimura N., Matsuo M.,
RA   Mizusawa H., Tanaka N., Koyama H., Namba M., Kanamaru R., Kuroki T.;
RT   "Screening the p53 status of human cell lines using a yeast functional
RT   assay.";
RL   Mol. Carcinog. 19:243-253(1997).
//
RX   PubMed=22490663; DOI=10.1016/j.bbrc.2012.03.122;
RA   Saiki Y., Yoshino Y., Fujimura H., Manabe T., Kudo Y., Shimada M.,
RA   Mano N., Nakano T., Lee Y., Shimizu S., Oba S., Fujiwara S.,
RA   Shimizu H., Chen N., Nezhad Z.K., Jin G., Fukushige S., Sunamura M.,
RA   Ishida M., Motoi F., Egawa S., Unno M., Horii A.;
RT   "DCK is frequently inactivated in acquired gemcitabine-resistant human
RT   cancer cells.";
RL   Biochem. Biophys. Res. Commun. 421:98-104(2012).
//
RX   PubMed=27231123; DOI=10.1158/2159-8290.CD-15-1442;
RA   Saha S.K., Gordan J.D., Kleinstiver B.P., Vu P., Najem M.S., Yeo J.-C.,
RA   Shi L., Kato Y., Levin R.S., Webber J.T., Damon L.J., Egan R.K.,
RA   Greninger P., McDermott U., Garnett M.J., Jenkins R.L.,
RA   Rieger-Christ K.M., Sullivan T.B., Hezel A.F., Liss A.S., Mizukami Y.,
RA   Goyal L., Ferrone C.R., Zhu A.X., Joung J.K., Shokat K.M., Benes C.H.,
RA   El-Bardeesy N.;
RT   "Isocitrate dehydrogenase mutations confer dasatinib hypersensitivity
RT   and SRC dependence in intrahepatic cholangiocarcinoma.";
RL   Cancer Discov. 6:727-739(2016).
//
RX   PubMed=31077409; DOI=10.1002/hep.30704;
RA   Sittithumcharee G., Suppramote O., Vaeteewoottacharn K.,
RA   Sirisuksakun C., Jamnongsong S., Laphanuwat P., Suntiparpluacha M.,
RA   Matha A., Chusorn P., Buraphat P., Kakanaporn C., Charngkaew K.,
RA   Silsirivanit A., Korphaisarn K., Limsrichamrern S., Tripatara P.,
RA   Pairojkul C., Wongkham S., Sampattavanich S., Okada S.,
RA   Jirawatnotai S.;
RT   "Dependency of cholangiocarcinoma on cyclin D-dependent kinase
RT   activity.";
RL   Hepatology 70:1614-1630(2019).
//
RX   PubMed=32899426; DOI=10.3390/cancers12092510;
RA   Scherer D., Davila Lopez M., Goeppert B., Abrahamsson S.,
RA   Gonzalez Silos R., Nova I., Marcelain K., Roa J.C., Ibberson D.,
RA   Umu S.U., Rounge T.B., Roessler S., Lorenzo-Bermejo J.;
RT   "RNA sequencing of hepatobiliary cancer cell lines: data and
RT   applications to mutational and transcriptomic profiling.";
RL   Cancers (Basel) 12:2510.1-2510.14(2020).
//
RX   PubMed=35640676; DOI=10.1016/j.ajpath.2022.05.007;
RA   Isidan A., Yenigun A., Soma D., Aksu E., Lopez K., Park Y.,
RA   Cross-Najafi A., Li P., Kundu D., House M.G., Chakraborty S.,
RA   Glaser S., Kennedy L., Francis H., Zhang W.-J., Alpini G.D., Ekser B.;
RT   "Development and characterization of human primary cholangiocarcinoma
RT   cell lines.";
RL   Am. J. Pathol. 192:1200-1217(2022).
//